Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated August 2015)* 5 stage 2 and ACC/AHA stage 1 to a systolic goal of <130 mmHg. Furthermore, the new Process Quality Measures are intended for use in quality improvement initiatives that are designed to take into account management and control for all ACC/AHA stages of HBP without creat- ing controversy or conflict with CMS, NCQA, NQF, and professional societies with differing recommendations and points of view about treatment of ACC/AHA stage 2 and stage 1 HBP. CMS recently determined that the evi- dence is sufficient to cover ambulatory BP monitoring for the diagnosis of hypertension in Medicare beneficiaries with suspected white coat or masked hypertension.11,12 Annals of Internal Medicine also published an In the Clinic section for screening, prevention, diagnosis, and treatment of hypertension, citing the 2017 Hypertension Clinical Practice Guidelines.13 The writing committee was also interested in trans- lating some of the 2017 Hypertension Clinical Practice Guidelines recommendations for systematic strategies that support the consistent and accurate diagnosis and treatment of populations of patients with HBP.4 In its deliberations on this challenge, the writing committee felt that it would be cumbersome and challenging to collect data at the patient and individual clinician levels, thereby limiting the use and utility of measures speci- fied at these levels. 